INTRODUCTION
============

Stress ulcer-related gastrointestinal bleeding is a potential complication of critical illness, for which the pathophysiology is complex. Systemic hemodynamic and local alterations result in gastric mucosal blood flow impairment with subsequent ischemic mucosal injury. However, the crucial factor for the development of ulceration and gastric bleeding is the high gastric intraluminal acidity, which is potentiated by fasting.^([@r1])^ This provides the rationale for the use of acid-suppressive drugs for pharmacological prophylaxis.^([@r2])^

Endoscopically evident upper gastrointestinal lesions may be found in up to 90% of critically ill patients within 3 days of admission;^([@r3])^ less than 50% of patients will have occult bleeding (defined as guaiac-positive gastric aspirate or guaiac-positive stool) and approximately 5%^([@r4],[@r5])^ will have overt bleeding (defined as hematemesis, bloody gastric aspirate, melena, or hematochezia). However, this does not necessarily translate into clinically significant gastrointestinal bleeding (deﬁned as overt bleeding in the presence of hypotension, tachycardia or orthostasis, a drop in hemoglobin of \> 2g/dL, or the need for surgery),^([@r6])^ whose incidence seems to have decreased over the years. In studies published before 1999, the incidence of clinically significant gastrointestinal bleeding was between 2% and 6% in patients not receiving prophylaxis.^([@r6])^ However, in studies published since 2001, the incidence has been reported to range between 0.1% and 4% with or without prophylaxis,^([@r7])^ which is related to better overall critical care, including the increased use of early enteral feeding. This, along with concerns related to the reported increasing frequency of infectious complications (nosocomial pneumonia and *Clostridium difficile* infections),^([@r8],[@r9])^ has challenged the traditional cornerstone of pharmacological prophylaxis with agents that suppress gastric acid for stress ulcer prophylaxis.^([@r10])^

This guideline from the *Sociedade Portuguesa de Cuidados Intensivos* aims to summarize current evidence and give clinical recommendations for the use of stress ulcer prophylaxis in the intensive care unit (ICU) to provide a standardized prescribing policy and avoid injudicious use.

METHODOLOGY
===========

A multidisciplinary task force was assembled. The task force comprised physicians (specialists in gastroenterology and intensive care medicine), nurses, pharmacists and economists with special interest and expertise in stress ulcer prophylaxis and/or evidence-based medicine. All members of the task force declared that no conflict of interest influenced the development of the guidelines.

Task force members participated in a discussion via e-mail, and six clinical questions were built for evidence evaluation. Each working member took charge of one clinical question and built search queries in the PICO (Participants, Interventions, Comparisons, and Outcomes) format.^([@r11])^ The availability of a Cochrane review^([@r12])^ relevant to the clinical questions was confirmed by searching the Cochrane Database of Systematic Reviews. A further complementary literature search of PubMed^®^ was performed. Trial data identified by the search strategies were considered to represent the best-quality evidence. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system principles^([@r13])^ was used to assess the quality of evidence from high to very low and to determine the strength of recommendations.

Finally, the task force determined the direction (for or against) and strength (strong or weak) of the recommendations using a two-round (self-administered questionnaire with no meetings among the participants) simple Delphi method.^([@r14])^ This was done according to the GRADE system and considered the following factors: evidence quality, certainty in the balance between advantages and disadvantages, certainty or similarity in values and preferences, and resource implications. Arriving at a consensus required an average level of agreement of ≥ 80%. When the agreement level was \< 80%, further discussions and voting were conducted.

A strong recommendation was worded as \"we recommend\" and a weak recommendation as \"we suggest\".

The key recommendations were presented at the annual symposium of the *Sociedade Portuguesa de Cuidados Intensivos* in Oporto and discussed by the panel and audience members.

STATEMENTS
==========

Statement 1
-----------

**We recommend** maintaining (or initiating) agents that suppress gastric acid (namely, proton-pump inhibitors) in patients with compelling indications for acid suppression. **Strong recommendation, moderate quality of evidence**.

Rational
--------

Several clinical situations require gastric acid suppression (namely, proton-pump inhibitors), and indications should be respected, both in the ambulatory and hospital (including intensive care) settings.

Patients with compelling indications include the following:

\- Known peptic ulcer disease in the healing phase and maintenance phase in selected circumstances \[\> 50 years old; multiple comorbidities; persistent symptoms; NSAID-negative and *Helicobacter pylori*-negative ulcers; need to continue NSAID or failure to eradicate *Helicobacter pylori*; ulcers complicated at the outset; and giant (\> 2cm), refractory or recurrent ulcers\].^([@r15])^- Treatment of *Helicobacter pylori* infection.^([@r16])^- Zollinger-Ellison syndrome and other hypersecretory conditions.^([@r17])^- Gastroesophageal reflux disease and acid-related complications (i.e., erosive esophagitis or peptic stricture)^([@r18])^ and Barrett\'s esophagus.^([@r19])^- Eosinophilic esophagitis.^([@r20])^- Dual antiplatelet therapy or concomitant anticoagulant therapy.^([@r21])^

Other approved indications (which should be discussed on a case-by-case basis) include the following:

\- Uninvestigated dyspepsia^([@r22])^ and epigastric pain syndrome.^([@r23])^

Approved indications may vary with specific acid suppressants, and therefore labeling indications should be considered.

Statement 2
-----------

**We recommend** prophylaxis with agents that suppress gastric acid rather than no prophylaxis in patients who have one *major* risk factor or two *minor* risk factors for stress ulceration.

**Strong recommendation, low quality of evidence**.

Rational
--------

Meta-analysis and systematic reviews^([@r6],[@r24],[@r25])^ have consistently shown that agents that suppress gastric acid (namely, histamine-2-receptor antagonists and/or proton-pump inhibitors) are superior to placebos in reducing the risk of clinically significant gastrointestinal bleeding. However, a recent meta-analysis^([@r26])^ suggested that in patients receiving enteral feeding, pharmacologic prophylaxis of stress ulcers is not beneficial, and combined interventions may even increase the risk of some infectious complications. This metanalysis has been criticized, and a number of large phase-III trials comparing pharmacological prophylaxis and placebos are under way. Their results and subsequent updated meta-analyses are expected to provide important, more relevant data on the balance between the benefits and harms of stress ulcer prophylaxis.^([@r27])^

Importantly, the incidence of stress ulcer-related gastrointestinal bleeding is not equally shared across the spectrum of patients admitted to intensive care, and certain patients appear more at risk for bleeding.

A large multicenter prospective cohort study^([@r4])^ identified coagulopathy (defined as a platelet count \< 50,000/m^3^, an international normalized ratio greater than 1.5, or a partial thromboplastin time greater than 2 times the control value) and respiratory failure (defined as the need for mechanical ventilation for at least 48 hours) as major risk factors for clinically significant gastrointestinal bleeding. The robustness of these risk factors has been confirmed in at least one additional small observational study.^([@r28])^

Older studies have been criticized because clinical practice has undergone major changes^([@r10])^ in the last 20 years, which have reduced the incidence of stress ulcer-related gastrointestinal bleeding. Moreover, in line with what was previously described, a recent exploratory randomized clinical trial^([@r29])^ comparing pharmacologic prophylaxis (with proton-pump inhibitors) and a placebo in mechanically ventilated critically ill patients anticipated to receive enteral nutrition did not show any benefit (or harm) of acid suppression. Because this was a feasibility trial, no firm evidence could be inferred, and the final conclusion was that it is possible to administer pharmacologic prophylaxis promptly after commencing mechanical ventilation.

Patients with traumatic brain injury (Glasgow Coma Scale score ≤ 8), traumatic spinal cord injury, or burn injury (\> 35% of the body surface area) have been routinely excluded from these studies because of a presumed high-risk of stress ulcer-related gastrointestinal bleeding most likely mediated through neurological pathways.^([@r30])^ Nevertheless, small randomized controlled trials^([@r31]-[@r33])^ with different acid suppression regimens have demonstrated significant protection from stress ulcer-related gastrointestinal bleeding in these high-risk populations.

No study has been performed specifically for sepsis; however, stress ulcer prophylaxis has been an integral part of the care of septic patients and is recommended by current guidelines.^([@r34])^ This makes sense regarding the new sepsis definitions^([@r35])^ in which the infection-related dysregulated host response has to be associated with a severe (life-threatening) organ dysfunction (identified as an acute change in total SOFA score ≥ 2 points), and thus includes multiple risk factors.

The evidence supporting other minor risk factors for stress ulcer-related gastrointestinal bleeding is weak as a result of a high risk of systematic and random errors. However, an increasing number of risk factors is associated with an increased risk of bleeding,^([@r36])^ and international guidelines recommended stress ulcer prophylaxis for patients with two or more risk factors.^([@r37])^ In the original description of stress-ulcer bleeding, hypotension (alongside sepsis and respiratory failure) was associated with stress-related mucosal damage.^([@r38])^ A recent inception cohort study identified the presence of three or more comorbidities (including glucocorticoid therapy), preexisting liver disease, renal failure (with use of renal replacement therapy), and coexisting or acute coagulopathy and higher SOFA-score, as significant risk factors for stress-ulcer bleeding after multivariate analysis.^([@r39])^ In another large cohort study,^([@r40])^ acute kidney injury (assessed by maximum serum creatinine level) was independently associated with an increased risk of gastrointestinal bleeding in patients mechanically ventilated for more than 48 hours. Additionally, a small prospective randomized trial^([@r33])^ demonstrated independent significance for the injury severity score.

Statement 3
-----------

**We recommend** the use of a proton-pump inhibitor when prophylaxis with agents that suppress gastric acid is indicated. **Strong recommendation, low quality of evidence**.

Rational
--------

The choice of the pharmacological prophylaxis agent should take into account factors related to effectiveness, adverse effects and cost.

Sucralfate, a mucosa-protective agent, alone has traditionally been considered inferior to histamine-2-receptor antagonists for stress ulcer prophylaxis.^([@r6],[@r41])^ While this has been challenged in a recent meta-analysis of randomized controlled trials,^([@r42])^ the results have been criticized because of significant heterogeneity between studies, of which only three had clinically significant gastrointestinal bleeding as a reported outcome.^([@r43])^

The efficacy of proton-pump inhibitors and histamine-2-receptor antagonists in preventing stress-ulcer bleeding in critically ill patients has been compared in several randomized control trials and meta-analyses.^([@r25],[@r44]-[@r48])^ The most recent and complete meta-analyses of randomized controlled trials^([@r25],[@r44])^ consistently demonstrated that proton-pump inhibitors were more effective than histamine-2-receptor antagonists at reducing clinically significant gastrointestinal bleeding, although this was not accompanied by a reduction in ICU mortality or length of stay. The robustness of these conclusions is limited by the trial methodologies, differences between lower and higher quality trials, sparse data and possible publication bias. An ongoing cluster-randomized crossover trial \[Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG): study number 1415-01\] is comparing proton-pump inhibitors and histamine-2-receptor antagonists, and the results are expected to provide more relevant data.^([@r27])^

There are multiple pharmacoeconomic analyses^([@r49]-[@r51])^ focused on the comparison between histamine-2-receptor antagonists and proton pump inhibitors for the prophylaxis of stress ulcerrelated gastrointestinal bleeding. The results are contradictory, mainly due to the use of different clinical inputs, and there is no strong evidence regarding which is the most effective alternative. Data from the most recent meta-analysis of clinical trials indicate that proton pump inhibitors should be used. However, if one relies on a propensity score-matched observational cohort study, histamine-2-receptor antagonists are the preferred option.^([@r51])^ The only clear conclusion is that, as the cost of prophylaxis is small when compared to the costs of complications, the most effective alternative will constitute a dominant alternative.^([@r51])^

Although the quality of evidence is suboptimal, proton-pump inhibitors have been the preferred regimen in intensive care units across Europe, the United States and Canada.^([@r52],[@r53])^ It is acknowledged that the published literature on this issue derives from heterogeneous populations of critically ill patients who may differ from the populations at risk identified by the previous recommendation.

Additionally, the expected adverse effects of proton-pump inhibitors are a concern and must be taken into account. A cohort study^([@r54])^ provided evidence of an increase in pneumonia with proton-pump inhibitor use; however, this study was related only to cardiac surgery patients, and confidence intervals were wide. Small randomized trials ^([@r29],[@r55]))^ and a case-control study showed an increased adjusted risk for *Clostridium difficile* infections during treatment with proton-pump inhibitors, but this was more related to the duration of exposure.^([@r56])^

Ultimately, the desirable consequences of stress ulcer prophylaxis with proton-pump inhibitors are expected to outweigh the undesirable consequences among the population at risk.

Statement 4
-----------

**We make no recommendation** regarding specific proton-pump inhibitor regimens.

Rational
--------

The ideal drug regimen should be effective in reducing the risk of ulceration, with a low potential for adverse effects and drug interactions and pharmacokinetic characteristics that facilitate its use in patients with organ dysfunction; it should also be cost-effective.

There is no direct comparison between different proton-pump inhibitor-based regimens (including drug, dosing, route of administration and galenic formulation), and heterogeneity across studies (comparing proton-pump inhibitors to other regimens) impairs the comparison of effects between the individual proton-pump inhibitor regimens tested to date. An *a priori* defined subgroup analysis of at least one meta-analysis suggests that the route of administration (enteral *versus* intravenous) and dosing (once *versus* twice a day) do not affect the results.^([@r43],[@r45])^

In relation to the route of administration, multiple factors (*e.g.,* vasopressor use, altered gastric emptying and motility, feeding tube and nutrient interactions) may influence enteral absorption in critically ill patients, and the intravenous route is generally preferred.^([@r57])^ This is disputed by a study showing that, despite a lower bioavailability, enteral lansoprazole suppressed acid in intensive care unit patients better than the intravenous formulation.^([@r58])^ However, this has not been confirmed by further studies, and lansoprazole requires a complex and labor-intensive galenic formulation for feeding tube administration.

Due to its safety in (at least moderate) organ dysfunction, lower probability of drug-drug interactions, and available formulations, intravenous pantoprazole (40mg *qd*) may be a reasonable choice.^([@r59])^ However, the definitive choice of the specific proton-pump inhibitor regimen should be based on individual patient and medical values, experience, product labeling, cost-benefit analyses, anticipated risks of drug-drug interactions and adverse effects.

Statement 5
-----------

**We suggest** using histamine-2-receptor antagonists in patients with *Clostridium difficile* infection and indications for stress ulcer prophylaxis. **Weak recommendation, very low quality of evidence**.

Rational
--------

Accumulating evidence suggests that the use of agents that suppress gastric acid may increase the frequency of infectious complications.^([@r8],[@r9],[@r60])^ The most recent and comprehensive meta-analysis^([@r61])^ found that therapy with agents that suppress gastric acid was associated with a significant risk of *Clostridium difficile* infections but that the risk was lower for histamine-2-receptor antagonists than with proton-pump inhibitors.

In the critically ill population, the increased risk for *Clostridium difficile* infections is still controversial because meta-analysis is weak in detecting a modest increase in these events.^([@r62])^ Nevertheless, the risk of *Clostridium difficile* infections remains higher in patients receiving proton-pump inhibitors compared with patients receiving histamine-2-receptor antagonists.^([@r8])^ Moreover, observational studies^([@r63],[@r64])^ have shown that continued proton-pump inhibitor use during incident *Clostridium difficile* infections increases the risk of recurrence.

Based on available data and given the significant disease burden and mortality associated with *Clostridium difficile* infections, proton-pump inhibitors should be avoided, and histamine-2-receptor antagonists should be the preferred therapy when stress ulcer prophylaxis is indicated.^([@r62])^

Statement 6
-----------

**We recommend** stopping prophylaxis with agents that suppress gastric acid when risk factors are no longer present and the patient is receiving enteral nutrition. **Strong recommendation, low quality of evidence**.

Rational
--------

Acid suppressants are inappropriately continued in a large proportion of patients after the resolution of risk factors and even after intensive care unit or hospital discharge, thus extending the potential risks and costs associated with stress ulcer prophylaxis beyond the intensive care unit.^([@r65])^ This is in agreement with studies that have concluded that 88.5% of stress ulcer prophylaxis in nonintensive care unit patients is inappropriate^([@r66])^ and that a relatively restrictive stress ulcer prophylaxis program not only reduces inappropriate use without increasing the rates of hospital-related gastrointestinal bleeding but also results in an estimated annualized cost savings of more than US\$ 200.000.^([@r67])^

As previously described,^([@r26])^ there is some evidence to suggest that in patients receiving enteral feeding, pharmacologic stress ulcer prophylaxis is not beneficial, and combined interventions may even increase the risk of some infectious complications. However, the evidence is still insufficient to justify withholding stress ulcer prophylaxis from patients who are at high risk for gastrointestinal bleeding. It is sufficiently compelling to support the cessation of prophylaxis when risk factors are no longer present and the patient is receiving enteral nutrition.

Patients should thus be evaluated daily during multidisciplinary care rounds for the continued need for prophylaxis, and once the patient is receiving enteral nutrition and risk factors are no longer present, stress ulcer prophylaxis should be discontinued. This strategy will reduce the overuse and unnecessary continuation of agents that suppress gastric acid upon discharge and in the outpatient setting.^([@r68])^ As one of the more common indications for stress ulcer prophylaxis is mechanical ventilation, extubation is crucial to identify and possibly discontinue acid suppression therapy.^([@r62])^

General algorithm
-----------------

The general algorithm for the prophylaxis of stress ulcer bleeding in the intensive care unit is presented in [figure 1](#f1){ref-type="fig"}. Patients with compelling indications for acid suppression should have an acid-suppressive regimen in accordance with the indication (Statement 1). Then, the risk for bleeding should be considered in each patient; the use of stress ulcer prophylaxis is appropriate for those with high risk. Patients at low risk should not start (or discontinue if previously initiated) stress ulcer prophylaxis (Statement 2). When a stress ulcer prophylaxis is recommended, the use of a proton-pump inhibitor is indicated (Statement 3) with no specific recommended regimen (Statement 4). The exception is cases of *Clostridium difficile* infection, for which histamine-2-receptor antagonists are preferred (Statement 5). Once the patient is receiving enteral nutrition and risk factors are no longer present, stress ulcer prophylaxis should be discontinued (Statement 6). [Table 1](#t2){ref-type="table"} compares the different available proton-pump inhibitor- and histamine-2-receptor antagonist-based regimens.

Figure 1Algorithm for prophylaxis of stress ulcer bleeding in the intensive care unit.\* If *Clostridium difficile* infection and indications for stress ulcer prophylaxis favor histamine-2-receptor antagonists. INR - International Normalized Ratio; aPPT - activated partial thromboplastin time; SOFA - Sequential Organ Failure Assessment.

###### 

Comparison of the different available proton-pump inhibitor- and histamine-2-receptor antagonist-based regimens

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                      Pharmaceutical formulation                                                                                                             Dosing       Dosing and route of administration   Reconstitution and administration                                                                                                                 Dose adjustment                              Relevant *major* pharmacological interactions (grade 1 - 2 impact)
  ----------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ------------ ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- --------------------------------------------------------------------
  Pantoprazole                              Powder for injection solution                                                                                                          40mg *qd*    Intravenous                          Reconstitute 40mg with 10cc of 0.9% NaCl and administer for 2 minutes (if necessary dilute in 100cc of 0.9% NaCl or 5% dextrose in H~2~O)         Hepatic failure (moderate to severe)         Azoles[\*](#TFN5){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                                                                                                                                    Reverse protease inhibitors[†](#TFN6){ref-type="table-fn"}

  Gastroresistant tablet                    Oral[\*](#TFN5){ref-type="table-fn"}                                                                                                   --                                                                                                                                                                                                                                               

  Omeprazole                                Powder for injection solution                                                                                                          40mg *qd*    Intravenous                          Reconstitute 40mg with 5cc of 0.9% NaCl and administer for 20 - 30 minutes (if necessary dilute in 100cc of 0.9% NaCl or 5% dextrose in H~2~O)    Hepatic failure (moderate to severe)         Azoles[†](#TFN6){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                                                                                                                                    Reverse protease inhibitors[†](#TFN6){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                                                                                                                                    Clopidogrel[‡](#TFN7){ref-type="table-fn"}

  Gastroresistant capsule                   Oral                                                                                                                                   --                                                                                                                                                                                                                                               

  Endogastric or endojejunal feeding tube   Open capsules, disperse the content in 40mL of non-carbonated water, shake vigorously and allow to stand for 2 minutes (until thick)                                                                                                                                                                                                                                                    

  Lansoprozole                              Gastroresistant capsule                                                                                                                30mg *qd*    Oral                                 --                                                                                                                                                Hepatic failure (moderate to severe)         Azoles[†](#TFN6){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                                                                                                                                    Reverse protease inhibitors[†](#TFN6){ref-type="table-fn"}

  Endogastric or endojejunal feeding tube   Open capsules and disperse the content in 40mL of (orange or apple) juice                                                                                                                                                                                                                                                                                                               

  Orodispersible tablet                     Oral                                                                                                                                   --                                                                                                                                                                                                                                               

  Endogastric or endojejunal feeding tube   Disperse in 10mL of non-carbonated water                                                                                                                                                                                                                                                                                                                                                

  Esomeprazole 40mg i.v. qd                 Powder for injection solution                                                                                                          40mg *qd*    Intravenous                                                                                                                                                                            Hepatic failure (moderate to severe)         Azoles[†](#TFN6){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                                                                                                                                    Reverse protease inhibitors[†](#TFN6){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                                                                                                                                    Clopidogrel[‡](#TFN7){ref-type="table-fn"}

  Gastroresistant capsule                   Oral                                                                                                                                   --                                                                                                                                                                                                                                               

  Endogastric or endojejunal feeding tube   Open capsules, disperse the granules in 40mL of non-carbonated water                                                                                                                                                                                                                                                                                                                    

  Gastroresistant tablet                    Oral                                                                                                                                   --                                                                                                                                                                                                                                               

  Ranitidine                                Powder for injection solution                                                                                                          50mg *tid*   Intravenous                          Reconstitute 50mg with 20cc of 0.9% NaCl and administer for 5 minutes\                                                                            Renal failure (clearance \< 50mL/min/m^2^)   Azoles[†](#TFN6){ref-type="table-fn"}
                                                                                                                                                                                                                                     *Continuous perfusion* : after a 50mg bolus (see above), dilute 150mg to 250cc of 0.9% NaCl or 5% dextrose in H~2~O in perfusion at 10.4cc/hour                                                

  Coated tablet                             150mg *qd*                                                                                                                             Oral         --                                                                                                                                                                                                                                  

  Endogastric or endojejunal feeding tube   Grind tablets and reduce to powder, and disperse the content in 40mL of non-carbonated water                                                                                                                                                                                                                                                                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

No data on enteral administration; consider alternative drugs;

consider alternative drugs;

consider substitution by pantoprazole.

NaCl - sodium chroride.

The authors suggest that the practices recommended in this guideline are continuously evaluated and monitored and that this guideline is updated as new evidence becomes available.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Major risk factor:
      - Coagulopathy (defined as a platelet count \< 50,000/m^3^, an International Normalized Ratio (INR) greater than 1.5, or a partial thromboplastin time greater than 2 times the control value).
      - Respiratory failure (defined as the need for mechanical ventilation for at least 48 hours).
      - Traumatic brain injury (Glasgow Coma Scale score ≤8), traumatic spinal cord injury, or burn injury (\>35% of the body surface area).
      - Sepsis (acute change in total Sequential Organ Failure Assessment - SOFA score ≥ 2 points consequent to infection).
  Minor risk factors:
      - Acute or chronic renal failure (needing intermittent or continuous renal replacement therapy).
      - Shock (defined as continuous infusion with vasopressors or inotropes, mean arterial blood pressure below 70mmHg or plasma lactate level equal to or greater than 4mmol/L).
      - Chronic hepatic failure (defined as cirrhosis proven by biopsy, history of variceal bleeding or hepatic encephalopathy).
      - Glucocorticoid therapy (≥ 250mg hydrocortisone equivalent per day).
      - Multiple trauma with an injury severity score ≥ 16.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
